This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of -31.43% and -20.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
by Zacks Equity Research
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of -51.61% and -40.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
by Ekta Bagri
We take a look at companies, which have been developing treatments for various diseases using RNAi technology.
Top Ranked Momentum Stocks to Buy for April 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 8th.
Top Ranked Momentum Stocks to Buy for November 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 23rd:
Options Traders Expect Huge Moves in Arbutus (ABUS) Stock
by Zacks Equity Research
Arbutus (ABUS) needs investors to pay close attention to the stock based on moves in the options market lately.
Arbutus Biopharma (ABUS) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
by Zacks Equity Research
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arbutus (ABUS) stock based on the movements in the options market lately.
Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation (ABUS)
5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.
Arbutus Biopharma (ABUS) Jumps: Stock Rises 9.6%
by Zacks Equity Research
Arbutus Biopharma (ABUS) was a big mover last session, as the company saw its shares rise more than 9% on the day, amid huge volumes.
Alexion to Restructure Operations, to Lower Headcount by 20%
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that it will undertake a restructuring plan to re-align the global organization and cut workforce.
Alexion (ALXN) Licenses Artubus Technology for Rare Diseases
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) has recently licensed Arbutus Biopharma proprietary LNP technology for use in rare disease programs.
Celgene Issues Preliminary 2016 Results, Lifts 2017 View
by Zacks Equity Research
Celgene (CELG) announced preliminary 2016 results and upped guidance for 2017 at the J.P. Morgan Healthcare Conference.
Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments
by Zacks Equity Research
Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.
Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
by Zacks Equity Research
Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
The Medicines Co LDL-Lowering Drug Positive in Phase II
by Zacks Equity Research
The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia.
Ultragenyx's (RARE) KRN23 Accepted for Review in the EU
by Zacks Equity Research
Ultragenyx (RARE) announced that EMA has accepted to review its MAA for KRN23 for the treatment of X-linked hypophosphatemia.
Bayer's sNDA for Stivarga Granted Priority Review in the U.S.
by Zacks Equity Research
Bayer (BAYRY) announced that the FDA has granted priority review designation to its sNDA for Stivarga for the second-line treatment of patients with uHCC.
Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data
by Zacks Equity Research
Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.
Innocoll (INNL) Down on FDA's Refusal to File Xaracoll NDA
by Zacks Equity Research
Innocoll (INNL) announced that it has received a Refusal to File letter from the FDA in connection with the NDA for Xaracoll for the treatment of postsurgical pain.